The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Abstract
PURPOSE: To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) and topotecan in patients with epithelial ovarian carcinoma that recurred after or didn’t respond to first-line, platinum-based chemotherapy. PATIENTS AND METHODS: Patients with measurable and assessable disease were randomized to receive either PLD 50 mg/m 2 as a 1-hour infusion every 4 weeks or topotecan 1.5 mg/m 2/d for 5 consecutive days every 3 weeks. Patients were stratified prospectively for platinum sensitivity and for the presence or absence of bulky disease. RESULTS: A total of 474 patients were treated (239 PLD and 235 topotecan). They comprised the intent-to-treat population. The overall progression-free survival rates were similar between the two arms (P = .095). The overall response rates for PLD and topotecan were 19.7% and 17.0%, respectively (P = .390). Median overall survival times were 60 weeks for PLD and 56.7 weeks for topotecan. Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from PLD for progression-free survival (P = .037), with medians of 28.9 for PLD versus 23.3 weeks for topotecan. For overall survival, PLD was significantly superior to topotecan (P = .008), with a median of 108 weeks versus 71.1 weeks. The platinum-refractory subgroup demonstrated a nonstatistically significant survival trend in favor of topotecan (P = .455). Severe hematologic toxicity was more common with topotecan and was more likely to be associated with dosage modification, or growth factor or blood product utilization. CONCLUSION: The comparable efficacy, favorable safety profile, and convenient dosing support the role of PLD as a valuable treatment option in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Transport of molecules across tumor vasculature
Jain, R. K. (1987) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00047468 · Cited by 866
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Dvorak, H. F., Nagy, J. A., Dvorák, J., & Dvořàk, A. M. (1988) · PubMed Central · Cited by 679
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
Self-citationMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Rose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386
Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336
Self-citationLund, B., Hansen, O. P., Theilade, K., Hansen, M., & Neijt, J. P. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1530 · Cited by 333
Bookman, M. A., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J. B., & Fields, S. Z. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3345 · Cited by 321
Self-citationGreene, R. F., Collins, J. M., Jenkins, J., Speyer, J. L., & Myers, C. E. (1983) · PubMed · Cited by 292
Eisenhauer, E. A., Vermorken, J. B., & van Glabbeke, M. (1997) · Annals of Oncology · doi:10.1023/a:1008240421028 · Cited by 265
Mackean, M., Planting, A., Twelves, C., Schellens, J., Allman, D., Osterwalder, B., Reigner, B., Griffin, T., Kaye, S., & Verweij, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2977 · Cited by 264
Shapiro, J. D., Millward, M. J., Rischin, D., Michael, M., Walcher, V., Francis, P. A., & Toner, G. C. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0284 · Cited by 250
Kudelka, A. P., Tresukosol, D., Edwards, C. L., Freedman, R. S., Levenback, C., Chantarawiroj, P., Gonzalez de Leon, C., Kim, E. E., Madden, T., Wallin, B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1552 · Cited by 246
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
Hoskins, P. J., & Swenerton, K. D. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.60 · Cited by 166
Friedlander, M. L., Millward, M., Bell, D., Bugat, R., Harnett, P. R., Moreno, J. A., Campbell, L., Varette, C., Ripoche, V., & Kayitalire, L. (1998) · Annals of Oncology · doi:10.1023/a:1008469212268 · Cited by 137
Vail, D. M., Chun, R., Thamm, D. H., Garrett, L., Cooley, A. J., & Obradovich, J. E. (1998) · PubMed · Cited by 122
Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes
Oudard, S. M., Thierry, A. R., Jorgensen, T. J., & Rahman, A. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685532 · Cited by 70
Treatment of refractory and recurrent ovarian cancer.
Ds, A. (1999) · PubMed · Cited by 65
Effect of liposomes on P-glycoprotein function in multidrug resistant cells
Thierry, A. R., Dritschilo, A., & Rahman, A. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91310-m · Cited by 62
Eksborg, S., Stendahl, U., & L�nroth, U. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00542426 · Cited by 51
Pegylated Liposomal Doxorubicin: Scientific Rationale and Preclinical Pharmacology
Martin, F. J. (1997) · Cited by 43
Cited by
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Metadata
- Authors
- Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-07-15
- Volume
- 19
- Issue
- 14
- Pages
- 3312-3322
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1960327677
- Cited by
- 1,211
- References
- 26
- FWCI
- 50.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.